SpringWorks Therapeutics is focused on developing targeted oncology treatments for rare diseases and cancer.

SpringWorks Therapeutics

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.

SpringWorks Therapeutics, Inc.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Dec 6, 2024 12:25 AM	a67585f0
public peers	general	Oct 2, 2024 1:14 PM	424aec86
news daily refresh	general	Dec 4, 2024 2:16 PM	dd143bac
news processing daily refresh	general	Dec 5, 2024 3:56 AM	5e41fccb
news impact assignment daily	general
news processing basic	general	Dec 5, 2024 3:59 AM	87202791
company summary	general
signals	general	Oct 2, 2024 1:14 PM	0abe8bcd
crunchbase trigger	general	Nov 27, 2024 12:50 PM	16a65dd0
crunchbase profile	general
li profile	general
translate crunchbase fundingrounds	general
peers	general	Oct 2, 2024 1:14 PM	92f61144
news basic	general	Dec 4, 2024 2:13 PM	f7c3191e
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:SPRINGWORKSTX

SpringWorks Therapeutics

Last Close

36.30

22/11 21:00

Market Cap

2.93B

Beta: -

Volume Today

1.41M

Avg: -